Market access

an opportunity to improve patient and market access at the local level –

As the new Health and Care Bill draws ever closer to Royal Assent, life science companies in the UK are preparing to navigate the most significant NHS legislation for a decade .

The new bill, due to come into force on July 1, will see clinical commissioning groups replaced by Integrated Care Systems (ICS) as statutory bodies across England. These ICS will consist of two parts – an Integrated Care Board (ICB), which will be responsible for strategic planning and allocation decisions across the NHS, and an Integrated Care Partnership (ICP), responsible for assembling the system partners and the development of an action plan for the public health and social protection needs in a given geographic area.

However, while this dramatic change in the UK market access environment aims to improve patient and provider care for life sciences companies, this uncharted territory presents both opportunities and challenges. So what are the key elements that decision makers need to address in order to develop successful future strategies?

The webinar will also cover:

  • Up-to-date analysis of the political, economic, social, technological, environmental and legal factors surrounding the new legislation
  • Top Issues Keeping Pharma & CNS Up At Night

About the panel

Ouday Bose, Country Managing Director and Head of Human Pharmacy, Boehringer Ingelheim. Uday Bose is a highly experienced and successful pharmaceutical industry leader within the human pharmacy sector, with over 25 years of experience in general management, health economics, sales and marketing. in national (UK/Ireland), regional (EMEA) and global roles. responsibility. He has significant experience in the specialty care space, including all aspects of commercializing early and late-stage assets, including 15 launches across 6 products. Since November 2018, Uday has served as Country Managing Director and Head of Human Pharmacy for Boehringer Ingelheim UK and Ireland. In May 2020, Uday was appointed to the Board of the Association of the British Pharmaceutical Industry (ABPI). He is also Chairman of the European Medicines Group.

MathiasMatthias Winker, Head of Integrated Care System Strategy, Buckinghamshire, Oxfordshire and West Berkshire. Matthias is an internationally experienced professional at a senior level in the healthcare industry with a focus on creating value for public and private provider organizations, commissioners, life science companies, governments and authorities. He has worked within the NHS on provider enterprise and clinical service strategies. In his current role, Matthias leads the strategic function of an integrated care system and works on the future positioning of CSI to achieve better outcomes, improve population health and drive economic and social growth overall. of the health and life sciences ecosystem. He holds a Masters in Health Economics and is an alumnus of Henley Business School.

Jim McArdle, Commercial Director, Interface Clinical Services, IQVIA. After graduating as a pharmacist, Jim worked in many areas of pharmacy in the UK and overseas. In 2006 Jim joined Interface Clinical Services as Chief Commercial Officer, responsible for strategy and growth, and has been a key contributor to the success of the organization. A strong believer in the role of clinical pharmacists, leveraging data to inform clinical and commissioning decisions, and patient-centric, Jim is considered a true innovator in healthcare. He has led many projects designed to improve the lives and well-being of patients in primary and secondary care and recognizes the value of collaborative work between the NHS and the life sciences sector to provide innovative solutions to cost savings. health and patients. Jim holds a BSc in Pharmacy from LJMU and an MBA from the University of Liverpool.

Dr. Paul Tunnah, Chief Content Officer and UK Managing Director, Healthware (moderator). Alongside his work as an acclaimed author, speaker, moderator and industry advisor, he founded the industry-leading publication pharmaphorum in 2009. Dr. Tunnah also holds a BA in Biochemistry and a Ph.D. in Biological Sciences from the University of Oxford, where his work focused on identifying new cancer therapies.

*When you click to register for this webinar, you will be redirected to a website operated by BrightTalk that hosts the webinar and collects your registration data.
This data may then be passed on to pharmaphorum media limited and then passed on to the company(ies) we partner with to bring you the webinar. This data may be used by us and by them for occasional marketing purposes. It will not be shared with other third parties.
By clicking to register for this webinar, you consent to all data you provide being used in this way.
If at any time you no longer wish to be contacted based on the information you provided when registering for this webinar, please email [email protected] requesting that your information be deleted in accordance to the General Data Protection Regulation.